EUVIMEDEUVIMED entdecken
Multizentrische Studie

Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China

Kun Hu, Yizhang Liu iD, Yang Sha, Mi Zhang, Lu Jian iD, Yongfang Duan, Chengzhi Lv, Yehong Kuang

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llae549 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Kun Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Latent Tuberculosis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New interleukin (IL)-17A inhibitors seem to demonstrate smaller effects on tuberculosis (TB) reactivation than expected.

Objectives

To evaluate the risk of TB reactivation, to assess serial interferon (IFN)-γ levels, and to weigh up the risks and benefits of TB chemoprophylaxis in patients with psoriasis treated with IL-17A inhibitors.

Methods

This dual-centre study included patients with psoriasis who were treated with IL-17A inhibitors. The incidence of active TB, serial IFN-γ levels tested by IFN-γ release assays (IGRAs), adverse events (AEs) and effectiveness were evaluated through 1 year in patients with psoriasis treated with IL-17A inhibitors. According to the chemoprophylaxis treatment regimen, patients with latent TB infection (LTBI) were classified into three groups: a complete chemoprophylaxis dose regimen (CCP), an incomplete chemoprophylaxis (ICCP) or no chemoprophylaxis (NCP).

Results

In 220 IGRA-negative patients, 17 of 220 (7.3%) became IGRA positive after receiving a mean of 69.1 weeks of IL-17A inhibitor treatment. Only one case of new-onset TB was observed after 52 weeks of ixekizumab therapy. Significant changes in IFN-γ levels were observed in IGRA-negative patients. Similarly, IFN-γ levels [listed as the mean (SD)] significantly increased at 1 year compared with baseline among IGRA-positive patients in the NCP [105 (68.7) vs. 236 (80.8) pg mL−1, P < 0.01] and ICCP [75.3 (48.3) vs. 608 (249) pg mL−1, P < 0.001] groups, whereas the changes were not significant [125 (26.6) vs. 131 (21.7) pg mL−1, P = 0.70] in the CCP group.

Conclusions

During IL-17A inhibitor therapy, there is a need for increased awareness of annual screening and assessment of individual risk for early detection of TB infection. LTBI treatment is generally well tolerated and is effective in preventing increased IFN-γ responses in patients with psoriasis treated with IL-17A inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisInterleukin-17Latent TuberculosisAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultChinaAgedInterferon-gammaInterferon-gamma Release Tests

Substanzen

Interleukin-17IL17A protein, humanAntibodies, Monoclonal, HumanizedInterferon-gammaixekizumabsecukinumabDermatologic Agents

Autor:innen und Institutionen

  • The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China.
  • Furong Laboratory, Changsha, Hunan, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China.
  • Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China.
  • Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China.

ORCID-Profile: Yizhang Liu, Lu Jian

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Hu, K., Liu, Y., Sha, Y., Zhang, M., Jian, L., Duan, Y., Lv, C., & Kuang, Y. (2025). Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae549

Vancouver

Hu K, Liu Y, Sha Y, Zhang M, Jian L, Duan Y, et al. Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llae549

BibTeX
@article{Hu2025,
  author = {Hu, Kun and Liu, Yizhang and Sha, Yang and Zhang, Mi and Jian, Lu and Duan, Yongfang and Lv, Chengzhi and Kuang, Yehong},
  title = {Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llae549}
}
Kostenlos starten →